Pulmatrix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulmatrix, Inc. on February 6, 2019, covering events occurring between February 3, 2019, and February 5, 2019. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The report focuses on capital structure adjustments and a recent equity offering:
- Equity Offering: On February 4, 2019, the Company closed an underwritten public offering of 532,353 shares of common stock.
- Warrants Issued: The Company issued warrants to purchase an aggregate of 34,605 shares of common stock at an exercise price of $2.125 per share.
- Reverse Stock Split: A 1-for-10 reverse stock split was approved by the Board on February 3, 2019, and became effective on February 5, 2019.
Material Changes
The primary material change reported is the execution of a 1-for-10 reverse stock split. Every 10 shares of issued and outstanding common stock were converted into one share. This adjustment also proportionately modified the exercise prices and share counts for outstanding preferred stock, stock options, and warrants. Fractional shares resulting from the split were rounded up to the nearest whole share. The Company's stock began trading on a split-adjusted basis on February 6, 2019, under the symbol "PULM" with a new CUSIP number of 74584P 202.
Outlook, Risks, and Management Commentary
Management commentary is limited to the execution of the previously authorized reverse stock split and the closing of the equity offering. The filing notes that the reverse stock split was authorized by stockholders in June 2018 within a range of 1-for-4 to 1-for-10. No specific forward-looking guidance, risk factors, or contingencies beyond the standard execution of these corporate actions are detailed in this specific filing.
Investor Verification Checklist
- Verify the post-split share count and the new CUSIP number (74584P 202) for trading purposes.
- Confirm the adjusted exercise prices and share quantities for any held stock options or warrants.
- Review the definitive proxy statement filed on April 26, 2018, for the full rationale behind the reverse stock split.
- Check the press release (Exhibit 99.1) for details on the use of proceeds from the 532,353 share offering.